Jason Gien
Concepts (327)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hernias, Diaphragmatic, Congenital | 36 | 2024 | 201 | 9.510 |
Why?
| | Extracorporeal Membrane Oxygenation | 17 | 2024 | 335 | 3.220 |
Why?
| | Acute Kidney Injury | 12 | 2023 | 812 | 2.120 |
Why?
| | Hypertension, Pulmonary | 16 | 2022 | 1925 | 1.930 |
Why?
| | Bronchopulmonary Dysplasia | 10 | 2023 | 387 | 1.760 |
Why?
| | Persistent Fetal Circulation Syndrome | 7 | 2016 | 137 | 1.570 |
Why?
| | rho-Associated Kinases | 5 | 2016 | 84 | 1.550 |
Why?
| | Infant, Newborn | 47 | 2024 | 6159 | 1.420 |
Why?
| | Neovascularization, Physiologic | 6 | 2013 | 182 | 1.350 |
Why?
| | Pulmonary Artery | 14 | 2018 | 1109 | 1.330 |
Why?
| | Endothelin-1 | 4 | 2016 | 177 | 1.270 |
Why?
| | Endothelial Cells | 10 | 2018 | 791 | 1.250 |
Why?
| | Nitric Oxide | 8 | 2020 | 893 | 1.180 |
Why?
| | Tracheostomy | 5 | 2016 | 133 | 0.980 |
Why?
| | Lung | 16 | 2024 | 4107 | 0.960 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2023 | 40 | 0.850 |
Why?
| | Ostomy | 1 | 2023 | 3 | 0.850 |
Why?
| | Respiration, Artificial | 4 | 2016 | 670 | 0.820 |
Why?
| | Infant | 24 | 2023 | 9586 | 0.780 |
Why?
| | PPAR gamma | 2 | 2013 | 180 | 0.770 |
Why?
| | Sheep | 14 | 2018 | 864 | 0.740 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 115 | 0.740 |
Why?
| | Patient Care Team | 3 | 2016 | 648 | 0.700 |
Why?
| | Prenatal Diagnosis | 3 | 2024 | 188 | 0.690 |
Why?
| | Ductus Arteriosus, Patent | 3 | 2023 | 52 | 0.690 |
Why?
| | Water-Electrolyte Imbalance | 4 | 2022 | 43 | 0.680 |
Why?
| | Retrospective Studies | 35 | 2024 | 15919 | 0.670 |
Why?
| | Length of Stay | 7 | 2019 | 1238 | 0.660 |
Why?
| | Reperfusion Injury | 1 | 2023 | 288 | 0.660 |
Why?
| | Blood Gas Analysis | 2 | 2021 | 83 | 0.650 |
Why?
| | Vasodilator Agents | 4 | 2016 | 329 | 0.630 |
Why?
| | Transportation of Patients | 1 | 2020 | 60 | 0.620 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2023 | 550 | 0.610 |
Why?
| | Bronchodilator Agents | 1 | 2020 | 197 | 0.590 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 326 | 0.590 |
Why?
| | Shock, Septic | 1 | 2020 | 210 | 0.550 |
Why?
| | Pregnancy | 20 | 2024 | 6872 | 0.550 |
Why?
| | Continuity of Patient Care | 2 | 2016 | 283 | 0.520 |
Why?
| | Trachea | 1 | 2018 | 255 | 0.480 |
Why?
| | Ventilator Weaning | 1 | 2016 | 37 | 0.480 |
Why?
| | Humans | 62 | 2024 | 139072 | 0.480 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2015 | 259 | 0.470 |
Why?
| | Hemodynamics | 4 | 2022 | 1093 | 0.470 |
Why?
| | Radial Artery | 1 | 2015 | 69 | 0.460 |
Why?
| | Umbilical Arteries | 1 | 2015 | 54 | 0.460 |
Why?
| | Vasoconstrictor Agents | 2 | 2018 | 133 | 0.440 |
Why?
| | Herniorrhaphy | 3 | 2020 | 70 | 0.440 |
Why?
| | Sepsis | 2 | 2020 | 612 | 0.440 |
Why?
| | Infant, Premature | 10 | 2023 | 580 | 0.430 |
Why?
| | Infant, Extremely Premature | 1 | 2014 | 66 | 0.420 |
Why?
| | Vasopressins | 1 | 2014 | 60 | 0.420 |
Why?
| | Central Nervous System Diseases | 1 | 2014 | 72 | 0.420 |
Why?
| | Female | 43 | 2024 | 74071 | 0.410 |
Why?
| | Hypotension | 1 | 2014 | 121 | 0.400 |
Why?
| | Weight Gain | 1 | 2017 | 543 | 0.390 |
Why?
| | Patient Discharge | 4 | 2021 | 915 | 0.390 |
Why?
| | Hernia, Diaphragmatic | 3 | 2021 | 66 | 0.390 |
Why?
| | Echocardiography | 5 | 2023 | 638 | 0.380 |
Why?
| | Oxygen Consumption | 1 | 2015 | 710 | 0.380 |
Why?
| | Hospital Mortality | 3 | 2021 | 920 | 0.380 |
Why?
| | Gastrostomy | 3 | 2023 | 118 | 0.370 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1570 | 0.360 |
Why?
| | Developmental Disabilities | 1 | 2014 | 268 | 0.360 |
Why?
| | Enzyme Activation | 1 | 2012 | 819 | 0.340 |
Why?
| | Animals, Newborn | 5 | 2023 | 859 | 0.320 |
Why?
| | Communication | 1 | 2016 | 932 | 0.320 |
Why?
| | Pulmonary Alveoli | 4 | 2014 | 408 | 0.300 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3640 | 0.300 |
Why?
| | Endothelium, Vascular | 3 | 2013 | 935 | 0.290 |
Why?
| | Kidney | 6 | 2023 | 1467 | 0.280 |
Why?
| | Bacteremia | 3 | 2019 | 214 | 0.280 |
Why?
| | Lung Volume Measurements | 3 | 2023 | 47 | 0.270 |
Why?
| | Cardiopulmonary Resuscitation | 2 | 2022 | 324 | 0.270 |
Why?
| | Sulfonamides | 3 | 2016 | 505 | 0.260 |
Why?
| | Survival Rate | 4 | 2022 | 1936 | 0.260 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2022 | 365 | 0.250 |
Why?
| | Animals | 18 | 2023 | 37261 | 0.250 |
Why?
| | Fetal Growth Retardation | 3 | 2018 | 558 | 0.250 |
Why?
| | Morbidity | 2 | 2023 | 321 | 0.240 |
Why?
| | Fetal Diseases | 1 | 2007 | 177 | 0.240 |
Why?
| | Male | 26 | 2024 | 68299 | 0.240 |
Why?
| | Receptors, Endothelin | 2 | 2016 | 49 | 0.230 |
Why?
| | Risk Factors | 9 | 2021 | 10390 | 0.230 |
Why?
| | Cells, Cultured | 8 | 2014 | 4183 | 0.230 |
Why?
| | Hirudins | 1 | 2024 | 52 | 0.220 |
Why?
| | Fetus | 6 | 2023 | 800 | 0.220 |
Why?
| | Antithrombins | 1 | 2024 | 62 | 0.220 |
Why?
| | Urinary Tract Infections | 4 | 2019 | 193 | 0.220 |
Why?
| | Signal Transduction | 6 | 2018 | 5095 | 0.220 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 88 | 0.210 |
Why?
| | Renal Replacement Therapy | 2 | 2022 | 89 | 0.210 |
Why?
| | Endotoxins | 2 | 2015 | 220 | 0.210 |
Why?
| | Hernia, Umbilical | 1 | 2023 | 20 | 0.210 |
Why?
| | Pulmonary Veins | 2 | 2014 | 106 | 0.200 |
Why?
| | Nitric Oxide Synthase Type III | 4 | 2013 | 200 | 0.200 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2853 | 0.200 |
Why?
| | Treatment Outcome | 7 | 2022 | 10930 | 0.200 |
Why?
| | Heparin | 1 | 2024 | 258 | 0.200 |
Why?
| | Fundoplication | 2 | 2020 | 56 | 0.190 |
Why?
| | Umbilical Cord | 1 | 2023 | 86 | 0.190 |
Why?
| | Pulmonary Circulation | 4 | 2014 | 438 | 0.190 |
Why?
| | Parturition | 1 | 2023 | 71 | 0.190 |
Why?
| | Tracheobronchomalacia | 1 | 2022 | 15 | 0.190 |
Why?
| | Biomarkers | 3 | 2024 | 4095 | 0.190 |
Why?
| | Fetal Blood | 1 | 2024 | 336 | 0.190 |
Why?
| | Tracheomalacia | 1 | 2022 | 17 | 0.190 |
Why?
| | Surgical Flaps | 2 | 2023 | 142 | 0.190 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 33 | 0.180 |
Why?
| | Gestational Age | 7 | 2021 | 918 | 0.180 |
Why?
| | Peptide Fragments | 1 | 2024 | 694 | 0.170 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 44 | 0.170 |
Why?
| | Guanylate Cyclase | 2 | 2011 | 38 | 0.170 |
Why?
| | Benzoates | 2 | 2011 | 46 | 0.160 |
Why?
| | Interactive Ventilatory Support | 1 | 2020 | 2 | 0.160 |
Why?
| | Analgesia | 1 | 2021 | 102 | 0.160 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1819 | 0.160 |
Why?
| | Serotonin | 2 | 2013 | 322 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 62 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 496 | 0.160 |
Why?
| | Anticoagulants | 1 | 2024 | 667 | 0.160 |
Why?
| | Infant Mortality | 2 | 2019 | 116 | 0.160 |
Why?
| | Prospective Studies | 5 | 2024 | 7666 | 0.160 |
Why?
| | Heart Failure | 2 | 2022 | 2065 | 0.150 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 2016 | 28 | 0.150 |
Why?
| | Thrombelastography | 1 | 2020 | 158 | 0.150 |
Why?
| | Heart Atria | 1 | 2020 | 137 | 0.150 |
Why?
| | Diuretics | 2 | 2018 | 71 | 0.150 |
Why?
| | Rats | 4 | 2023 | 5594 | 0.150 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 209 | 0.150 |
Why?
| | Asphyxia Neonatorum | 1 | 2018 | 18 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 176 | 0.140 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2018 | 23 | 0.140 |
Why?
| | MicroRNAs | 1 | 2024 | 676 | 0.140 |
Why?
| | Cell Proliferation | 3 | 2015 | 2482 | 0.140 |
Why?
| | Disease Models, Animal | 5 | 2015 | 4319 | 0.140 |
Why?
| | Child | 8 | 2022 | 21946 | 0.140 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 85 | 0.140 |
Why?
| | Administration, Inhalation | 2 | 2016 | 595 | 0.140 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 280 | 0.130 |
Why?
| | Survival Analysis | 2 | 2020 | 1311 | 0.130 |
Why?
| | Blood Vessels | 2 | 2016 | 180 | 0.130 |
Why?
| | Intensive Care Units, Neonatal | 5 | 2018 | 260 | 0.130 |
Why?
| | Brain Diseases | 1 | 2018 | 148 | 0.130 |
Why?
| | Injections, Intraperitoneal | 1 | 2016 | 114 | 0.130 |
Why?
| | Infant Care | 1 | 2016 | 45 | 0.130 |
Why?
| | Expectorants | 1 | 2016 | 23 | 0.130 |
Why?
| | Rats, Sprague-Dawley | 3 | 2016 | 2499 | 0.120 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 74 | 0.120 |
Why?
| | Ventilators, Mechanical | 1 | 2016 | 61 | 0.120 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2016 | 145 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.120 |
Why?
| | Bacterial Infections | 1 | 2018 | 245 | 0.120 |
Why?
| | Fluorescent Antibody Technique | 1 | 2016 | 386 | 0.120 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 17 | 0.120 |
Why?
| | Cross Infection | 1 | 2018 | 249 | 0.120 |
Why?
| | Steroids | 1 | 2016 | 163 | 0.120 |
Why?
| | Receptors, Calcitriol | 1 | 2015 | 55 | 0.120 |
Why?
| | Intubation, Intratracheal | 1 | 2018 | 279 | 0.110 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 45 | 0.110 |
Why?
| | Bleomycin | 1 | 2016 | 247 | 0.110 |
Why?
| | Preoperative Care | 1 | 2017 | 366 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2032 | 0.110 |
Why?
| | Peptides, Cyclic | 1 | 2016 | 265 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2024 | 3577 | 0.110 |
Why?
| | Piperidines | 1 | 2016 | 216 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 266 | 0.110 |
Why?
| | Databases, Factual | 5 | 2018 | 1412 | 0.110 |
Why?
| | Catalase | 1 | 2015 | 134 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 299 | 0.110 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 50 | 0.110 |
Why?
| | Adrenergic beta-Agonists | 1 | 2015 | 97 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 334 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 96 | 0.110 |
Why?
| | Arteriovenous Fistula | 1 | 2014 | 36 | 0.110 |
Why?
| | Cyclic GMP | 2 | 2011 | 91 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2015 | 104 | 0.110 |
Why?
| | Coculture Techniques | 1 | 2015 | 241 | 0.110 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2013 | 62 | 0.100 |
Why?
| | Capillaries | 1 | 2014 | 114 | 0.100 |
Why?
| | Logistic Models | 4 | 2020 | 2093 | 0.100 |
Why?
| | Pregnancy Trimester, Third | 2 | 2024 | 115 | 0.100 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2013 | 19 | 0.100 |
Why?
| | Ligation | 1 | 2012 | 93 | 0.100 |
Why?
| | Ductus Arteriosus | 1 | 2012 | 73 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 352 | 0.100 |
Why?
| | RNA, Small Interfering | 1 | 2015 | 626 | 0.090 |
Why?
| | Vitamins | 1 | 2014 | 188 | 0.090 |
Why?
| | Diaphragm | 2 | 2023 | 43 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1732 | 0.090 |
Why?
| | Amides | 1 | 2012 | 97 | 0.090 |
Why?
| | Pyridines | 2 | 2012 | 494 | 0.090 |
Why?
| | Hospitalization | 2 | 2021 | 2233 | 0.090 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 627 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 348 | 0.090 |
Why?
| | DNA Primers | 1 | 2012 | 509 | 0.090 |
Why?
| | RNA Interference | 1 | 2012 | 468 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2012 | 1092 | 0.080 |
Why?
| | Isoenzymes | 1 | 2011 | 304 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 850 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 874 | 0.080 |
Why?
| | Vitamin D | 1 | 2014 | 399 | 0.080 |
Why?
| | Protein Binding | 1 | 2016 | 2235 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 165 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1233 | 0.080 |
Why?
| | Ultrasonography, Prenatal | 2 | 2022 | 287 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1317 | 0.080 |
Why?
| | Amniotic Fluid | 2 | 2024 | 79 | 0.080 |
Why?
| | Prognosis | 3 | 2023 | 3999 | 0.080 |
Why?
| | Vasodilation | 2 | 2011 | 509 | 0.080 |
Why?
| | Hypoxia | 1 | 2016 | 1150 | 0.070 |
Why?
| | Myosin-Light-Chain Phosphatase | 1 | 2008 | 2 | 0.070 |
Why?
| | Dipeptides | 1 | 2008 | 51 | 0.070 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2023 | 358 | 0.070 |
Why?
| | Nitroarginine | 1 | 2007 | 57 | 0.070 |
Why?
| | Phosphorylation | 2 | 2011 | 1767 | 0.070 |
Why?
| | Enzyme Inhibitors | 2 | 2009 | 850 | 0.070 |
Why?
| | Incidence | 3 | 2019 | 2832 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1739 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1215 | 0.070 |
Why?
| | Pilot Projects | 2 | 2024 | 1766 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 242 | 0.060 |
Why?
| | Oxadiazoles | 3 | 2011 | 33 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2017 | 2721 | 0.060 |
Why?
| | Vascular Resistance | 3 | 2013 | 364 | 0.060 |
Why?
| | Pulmonary Edema | 1 | 2006 | 114 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 794 | 0.060 |
Why?
| | Hyperoxia | 1 | 2006 | 91 | 0.060 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 516 | 0.060 |
Why?
| | Child, Preschool | 2 | 2020 | 11171 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1355 | 0.060 |
Why?
| | Cell Membrane | 1 | 2008 | 716 | 0.060 |
Why?
| | Odds Ratio | 2 | 2018 | 1084 | 0.050 |
Why?
| | Phenotype | 2 | 2016 | 3145 | 0.050 |
Why?
| | Fetal Development | 1 | 2007 | 298 | 0.050 |
Why?
| | Liver | 2 | 2022 | 1807 | 0.050 |
Why?
| | Adult | 4 | 2024 | 38428 | 0.050 |
Why?
| | Indomethacin | 1 | 2023 | 87 | 0.050 |
Why?
| | Ketanserin | 2 | 2013 | 12 | 0.050 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.050 |
Why?
| | Sertraline | 2 | 2013 | 28 | 0.050 |
Why?
| | Water-Electrolyte Balance | 1 | 2022 | 31 | 0.050 |
Why?
| | Chronic Disease | 1 | 2008 | 1804 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 486 | 0.040 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2021 | 154 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 67 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 6 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 8 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3466 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 13378 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2022 | 528 | 0.040 |
Why?
| | Intubation | 1 | 2018 | 6 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 215 | 0.040 |
Why?
| | Oligohydramnios | 1 | 2018 | 12 | 0.040 |
Why?
| | Polyhydramnios | 1 | 2018 | 18 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 211 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 169 | 0.040 |
Why?
| | Apgar Score | 1 | 2018 | 18 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 96 | 0.040 |
Why?
| | Heart | 1 | 2022 | 612 | 0.040 |
Why?
| | Intensive Care, Neonatal | 1 | 2018 | 40 | 0.040 |
Why?
| | Surgical Mesh | 1 | 2018 | 52 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2018 | 126 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 6869 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 93 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 142 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2020 | 262 | 0.030 |
Why?
| | Pneumonia | 2 | 2018 | 644 | 0.030 |
Why?
| | Gene Expression | 2 | 2013 | 1488 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 557 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 521 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 2018 | 113 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 143 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 131 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 502 | 0.030 |
Why?
| | Adolescent | 1 | 2016 | 21594 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1085 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 273 | 0.030 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 119 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2049 | 0.030 |
Why?
| | Postpartum Period | 1 | 2019 | 346 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2015 | 15 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2016 | 81 | 0.030 |
Why?
| | Calcifediol | 1 | 2015 | 33 | 0.030 |
Why?
| | Birth Weight | 1 | 2018 | 515 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 434 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 827 | 0.030 |
Why?
| | United States | 3 | 2018 | 15078 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2020 | 745 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 199 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2018 | 888 | 0.030 |
Why?
| | Sheep, Domestic | 1 | 2013 | 34 | 0.030 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 172 | 0.020 |
Why?
| | Tryptophan Hydroxylase | 1 | 2013 | 53 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1092 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2013 | 198 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3276 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1498 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 423 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 9 | 0.020 |
Why?
| | Cell Aggregation | 1 | 2011 | 25 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 35 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 71 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 85 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2011 | 100 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 55 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5749 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2011 | 171 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 851 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 622 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2011 | 232 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2082 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1523 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 332 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 442 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2009 | 67 | 0.020 |
Why?
| | Piperazines | 1 | 2011 | 345 | 0.020 |
Why?
| | Oxygen | 1 | 2014 | 977 | 0.020 |
Why?
| | Acetylcholine | 1 | 2009 | 203 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 414 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2747 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 969 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2009 | 450 | 0.020 |
Why?
| | Organ Size | 1 | 2006 | 471 | 0.010 |
Why?
| | Body Weight | 1 | 2006 | 996 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2449 | 0.010 |
Why?
|
|
Gien's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|